Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non–Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance)

Authors :: Paula N. Friedman
Olwen Hahn
Lydia Hodgson
Karen L. Reckamp
Jon Ritter
Joan H. Schiller
Everett E. Vokes
Tom Stinchcombe
Richard T. Cheney
Maria Q. Baggstrom
T. Sachdev
Xiaofei Wang
Martin J. Edelman
Julian R. Molina
Erin M. Bertino
Ginger L. Milne
K. Mitchell-Edwards
Ajeet Gajra
Source :: International Journal of Radiation Oncology*Biology*Physics. 98:220-221
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Chemotherapy
Radiation
business.industry
medicine.medical_treatment
medicine.disease
Internal medicine
medicine
Celecoxib
Radiology, Nuclear Medicine and imaging
Non small cell
Lung cancer
business
medicine.drug

Full Text Access

Tools